21世纪经济报道记者季媛媛 在创新药行业依旧处于资本寒冬的“降本增效”主旋律中,君实生物交出了2025年成绩单。 3月13日晚间,君实生物(1877.HK,688180.SH)发布的2025年年度报告显示,公司在报告期内实现营业收入24.98亿元,同比增长28.23%;归母净亏损收窄至8.75亿元,同比大幅减亏31.68%。若剔除股权激励计划所对应的股份支付影响,归母净亏损将进一步降至7.99...
Source Link21世纪经济报道记者季媛媛 在创新药行业依旧处于资本寒冬的“降本增效”主旋律中,君实生物交出了2025年成绩单。 3月13日晚间,君实生物(1877.HK,688180.SH)发布的2025年年度报告显示,公司在报告期内实现营业收入24.98亿元,同比增长28.23%;归母净亏损收窄至8.75亿元,同比大幅减亏31.68%。若剔除股权激励计划所对应的股份支付影响,归母净亏损将进一步降至7.99...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.